Comparative in vitro and in vivo cytotoxic activity of (E)-5(2- bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2- bromovinyl)-1-β-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase

Cancer Gene Therapy

Volumn 7, Issue 2, 2000, Pages 215-223

  Grignet Debrus, Christine ^a,d   Cool, Vincent ^b   Baudson, Nathalie ^b   Degrève, Bart ^c   Balzarini, Jan ^c   De Leval, Laurence ^d   Debrus, Serge ^d   Velu, Thierry ^b   Calberg Bacq, Claire Michelle ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

BVaraU; BVDU; Herpes simplex viral thymidine kinases; Therapy; Varicella zoster

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; GANCICLOVIR; SORIVUDINE; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; GENE THERAPY; GLIOSARCOMA; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; VARICELLA ZOSTER VIRUS;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 3; MUS MUSCULUS; SIMPLEXVIRUS;

EID: 0034033272     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700108     Document Type: Article

References (42)

1. Mar E-C, Chiou J-F, Cheng Y-C, et al. Inhibition of cellular DNA polymerase α and human cytomegalovirus-induced DNA polymerase by triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Virol. 1985;53:776-780.
2. Balzarini J, De Clercq E, Ayusawa D, et al. Murine mammary FM3A carcinoma cells transformed with the Herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. FEBS Lett. 1985;185:95-100.
3. Balzarini J, De Clercq E, Verbruggen A, et al. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with Herpes simplex virus type 1 thymidine kinase gene. Mol Pharmacol. 1985;28:581-587.
4. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46: 5276-5281.
5. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 1997;3:1354-1361.
6. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated Herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther. 1998;9:1083-1092.
7. Grignet-Debrus C, Calberg-Bacq C-M. Potential of Varicella zoster virus thymidine kinase as a suicide gene in breast cancer cells. Gene Ther. 1997;4:560-569.
8. Roberts GB, Fyfe JA, McKee SA, et al. Varicella zoster virus thymidine kinase: characterization and substrate specificity. Biochem Pharmacol 1993;46:2209-2218.
9. Andrei G, Snoeck R, Reymen D, et al. Comparative activity of selected antiviral compounds against clinical isolates of Varicella zoster virus. Eur J Clin Microbiol Infect Dis. 1995;14:318-328.
10. Cheng Y-C, Dutschman G, Fox JJ, et al. Differential activity of potential antiviral nucleoside analogues on Herpes simplex virus-induced and human cellular thymidine kinases. Antimicrob Agents Chemother. 1981;20:420-423.
11. Field AK, Davies ME, De Witt C, et al. 9-{(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl}guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci USA. 1983;80:4139-4143.
12. De Clercq E, Zhang Z-X, Descamps J, et al. (E)-5-(2-bromovinyl)-2′-deoxyuridine vs. interferon in the systemic treatment of infection with Herpes simplex virus of athymic nude mice. J Infect Dis. 1981;143:846-852.
13. Maudgal PC, De Clercq E, Descamps J, et al. (E)-5-(2-bromovinyl)-2′-deoxyuridine in the treatment of experimental Herpes simplex keratitis. Antimicrob Agents Chemother. 1980;17:8-12.
14. Soike KF, Gibson S, Gerone PJ. Inhibition of simian Varicella virus infection of African green monkeys by (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU). Antiviral Res. 1981;1:325-337.
15. De Clercq E, Descamps J, De Somer P, et al. Pharmacokinetics of (E)-5-(2-bromovinyl)-2′-deoxyuridine in mice. Antimicrob Agents Chemother. 1979;16:234-236.
16. Wildiers J, De Clercq E. Oral (E)-5-(2-bromovinyl)-2′-deoxyuridine treatment of severe Herpes zoster in cancer patients. Eur J Cancer Clin Oncol. 1984;20:471-476.
17. Benoit Y, Laureys G, Delbeke M-J, et al. Oral BVDU treatment of varicella and zoster in children with cancer. Eur J Pediatr. 1985;143:198-202.
18. Wingard JR, Hess AD, Stuart RK, et al. Effect of several antiviral agents on human lymphocyte functions and marrow progenitor cell proliferation. Antimicrob Agents Chemother. 1983;23:593-597.
19. Sasadeusz JJ, Sacks SL. Systemic antivirals in herpesvirus infections. Dermatol Clin. 1993;11:171-185.
20. Machida H. Comparison of susceptibilities of Varicella zoster virus and Herpes simplex viruses to nucleoside analogs. Antimicrob Agents Chemother. 1986;29:524-526.
21. Whitley RJ. Sorivudine: a promising drug for the treatment of Varicella zoster virus infection. Neurology. 1995;45: S73-S75.
22. Degreve B, Andrei G, Izquierdo M, et al. Varicella zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer. Gene Ther. 1997;4:1107-1114.
23. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology. 1988;167:400-406.
24. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol. 1986;6:2895-2902.
25. Cool V, Pirotte B, Gérard C, et al. Curative potential of Herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma. Hum Gene Ther. 1996;7:627-635.
26. Sambrook J, Fritsch EF, Maniatis T. Assay for β-galactosidase in extracts of mammalian cells. In: Ford N, Nolan C, Ferguson M, eds. Molecular Cloning: A Laboratory Manual. 2nd ed. New York: Cold Spring Harbor Laboratory Press; 1989:16:66-16.67.
27. Balzarini J, Bohman C, De Clercq E. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase of Herpes simplex type 1 or type 2. J Biol Chem. 1993;268:6332-6337.
28. Bohman C, Balzarini J, Wigerinck P, et al. Mechanism of cytostatic action of novel 5-(thien-2-yl)- and 5-(furan-2-yl)-substituted pyrimidine nucleoside analogues against tumor cells transfected by the thymidine kinase gene of Herpes simplex virus. J Biol Chem. 1994;268:8036-8043.
29. Desgranges C, Razaka G, Rabaud M, et al. Phosphorolysis of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and other 5-substituted-2′-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets. Biochem Pharmacol. 1983;32:3583-3590.
30. Zimmerman M, Seidenberg J. Deoxyribosyl transfer: thymidine phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissues. J Biol Chem. 1964;239:2618-2621.
31. Snoeck R, Andrei G, Gérard M, et al. Successful treatment of progressive monocutaneous acyclovir- and foscarnet-resistant Herpes simplex virus infection with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis. 1994;18:570-578.
32. Balzarini J. Herpes simplex virus thymidine kinase gene-transfected tumor cells: sensitivity to antiherpetic drugs. Nucleosides Nudeotides. 1996;15:821-831.
33. Descamps J, Sehgal RK, De Clercq E, et al. Inhibitory effect of E-5-(2-bromovinyl)-1-β-D-arabinofuranosyluracil on Herpes simplex virus replication and DNA synthesis. J Virol. 1982;43:332-336.
34. Santi D. Perspectives on the design and biochemical pharmacology of inhibitors of thymidylate synthetase. J Med Chem. 1980;23:103-111.
35. Desgranges C, Razaka G, Bricaud H, et al. Inhibition and reversal of the degradation of the antiviral drug (E)-5-(2-bromovinyl)-2′-deoxyuridine in vivo. Biochem Pharmacol. 1985;34:405-406.
36. Balzarini J, Bohman C, Walker RT, et al. Comparative cytostatic activity of different antiherpetic drugs against Herpes simplex virus thymidine kinase gene-transfected tumor cells. Mol Pharmacol. 1994;45:1253-1258.
37. Ashida N, Sakata S, Kano F, et al. In vitro and in vivo anti-herpes viral activities and biological properties of CV-araU. Antiviral Res. 1994;25:179-184.
38. Degrève B, De Clercq E, Balzarini J. Bystander effect of purine nucleoside analogues in HSV-1 TK suicide gene therapy is superior to that of pyrimidine nucleoside analogues. Gene Ther. 1999;6:162-170.
39. Varela-Echevarria A, Prorock CM, Ron Y, et al. High rate of genetic rearrangement during replication of a Moloney murine leukemia virus-based vector. J Virol. 1993;67:6357-6364.
40. Tate PH, Bird AP. Effects of DNA methylation on DNA binding protein and gene expression. Curr Opin Genet Dev. 1993;3:226-231.
41. Benedetti S, Dimeco F, Pollo B, et al. Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Hum Gene Ther. 1997;8:1345-1353.
42. Golumbek PT, Hamzeh FM, Jaffee EM, et al. Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J Immunother. 1992;12:224-230.